J B Chemicals & Pharmaceuticals Ltd Share Price
As on 04 June 2026 at 20:15 IST
J.B. Chemicals & Pharmaceuticals Q1 FY26 Results:
Net profit after tax increased 14.5% to ₹202.4 crores in Q1 FY26, from ₹176.8 crores in Q1 FY25. Total income for the quarter increased 9.7% year-on-year to ₹1,108.5 crores, from ₹1,010.3 crores.
About J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) is a leading pharmaceutical company in India. It develops, manufactures, and markets pharmaceutical formulations, active pharmaceutical ingredients (APIs), and herbal remedies. The company was founded in 1976 by the Mody family. JBCPL was later acquired by global investment firm KKR in 2020, marking a significant transition in its ownership. The company is headquartered in Mumbai, Maharashtra. Its main products include Rantac (Ranitidine), Metrogyl (Metronidazole), and Cilacar (Cilnidipine). JBCPL focuses primarily on cardiovascular, gastrointestinal, and pain management segments. The company operates in the Healthcare sector, specifically in Pharmaceuticals. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
2.78%
Over 6 Months
21.35%
Over 1 Year
26.50%
Over 3 Years
101.98%
J B Chemicals & Pharmaceuticals Ltd Summary
Close ₹2,140
Open ₹2,121
High ₹2,149.20
Low ₹2,104
Volume 2,50,200
Net Turnover (in Cr) ₹53.38
52Wk High ₹2,285.30
52Wk Low ₹1,603.50
52Wk High / Low
1,603.50
2,285.30
J B Chemicals & Pharmaceuticals Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹34,359.56
EPS (TTM) 42.56
Book Value (BV) 251.48
Div. Yield 1.03 %
P/E (TTM) 50.96
Price/Book Value 8.51
Delivery % 75.41 %
Face Value 1
Key Ratios
PE Ratio 49.15
PB Ratio 8.20
EV to Sales 8.50
PEG Ratio 343.39
ROA 16.55
ROE 18.18
Debt-Equity -
Net Profit Margin 17.33
Operating Profit Margin 27.87
J B Chemicals & Pharmaceuticals Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 4,207.94 | 3,956.31 | 3,521.45 | 3,159.22 | 2,463.47 |
| Total Expenses | 3,228.42 | 3,068.92 | 2,769.94 | 2,603.99 | 1,958.57 |
| Profit Before Tax | 952.34 | 887.39 | 751.51 | 555.23 | 504.90 |
| Profit After Tax | 709.47 | 659.58 | 552.63 | 410.01 | 386.04 |
| Operating Profit After Depreciation | 985.08 | 899.12 | 795.84 | 591.29 | 510.02 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 1,898.18 | 1,984.54 | 2,017.47 | 1,911.75 | 1,281.76 |
| Total Non Current Assets | 2,059.27 | 2,351.04 | 2,140.78 | 2,025.84 | 1,354.24 |
| Total Current Assets | 2,909.37 | 1,922.74 | 1,853.35 | 1,528.03 | 1,253.16 |
| Total Assets | 4,968.65 | 4,273.78 | 3,994.13 | 3,553.87 | 2,607.40 |
| Total Shareholder's Fund | 4,159.22 | 3,433.32 | 2,923.33 | 2,480.35 | 2,134.12 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 703.92 | 902.45 | 800.61 | 625.61 | 170.13 |
| Net Cash Used In Investing Activities | -585.73 | -295.90 | -403.85 | -961.76 | 2.32 |
| Net Cash Used In Financing Activities | -123.10 | -579.67 | -385.49 | 356.54 | -138.39 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 3,945.17 | 3,757.66 | 3,333.32 | 2,892.81 | 2,228.49 |
| Total Expenses | 3,015.26 | 2,880.56 | 2,594.98 | 2,365.77 | 1,757.20 |
| Profit Before Tax | 902.73 | 877.11 | 738.34 | 527.04 | 471.29 |
| Profit After Tax | 674.10 | 652.54 | 543.36 | 388.89 | 361 |
| Operating Profit After Depreciation | 934.49 | 886.22 | 778.86 | 561.35 | 476.24 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 1,809.09 | 1,899.03 | 1,938.16 | 1,832.40 | 1,208.44 |
| Total Non Current Assets | 2,106.18 | 2,399.24 | 2,198.24 | 2,071.85 | 1,407.21 |
| Total Current Assets | 2,717.32 | 1,778.65 | 1,715.40 | 1,398.30 | 1,130.85 |
| Total Assets | 4,823.50 | 4,177.90 | 3,913.64 | 3,470.15 | 2,538.07 |
| Total Shareholder's Fund | 4,037.71 | 3,377.19 | 2,886.26 | 2,442.48 | 2,103.67 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 644.89 | 884.03 | 789.03 | 628.64 | 147.10 |
| Net Cash Used In Investing Activities | -587.06 | -289.93 | -412.47 | -955.86 | 4.18 |
| Net Cash Used In Financing Activities | -107.68 | -574.27 | -374.08 | 343.41 | -137.85 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 904.23 | 1,064.72 | 1,084.90 | 1,093.94 | 949.48 |
| Total Expenses | 703.10 | 768.90 | 775.30 | 793.07 | 723.04 |
| Profit Before Tax | 134.69 | 266.87 | 279.15 | 271.61 | 193.03 |
| Profit After Tax | 101.37 | 197.89 | 207.82 | 202.38 | 145.69 |
| Operating Profit after Depreciation | 213.11 | 314.10 | 324.94 | 315.42 | 240.92 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 836.43 | 990.91 | 1,022.65 | 1,039.90 | 901.34 |
| Total Expenses | 641.50 | 721.41 | 724.29 | 746.78 | 670.36 |
| Profit Before Tax | 128.10 | 241.18 | 268.49 | 264.96 | 199.17 |
| Profit After Tax | 96.54 | 179.27 | 200.42 | 197.87 | 149.80 |
| Operating Profit after Depreciation | 205.17 | 286.39 | 312.61 | 307.02 | 244.51 |
J B Chemicals & Pharmaceuticals Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 2,112.93
S2 2,085.87
S3 2,067.73
Pivot 2,131.07
R1 2,158.13
R2 2,176.27
R3 2,203.33
Moving Average
20 SMA 2,159.16
50 SMA 2,079.89
100 SMA 2,019.15
200 SMA 1,878.65
J B Chemicals & Pharmaceuticals Ltd Corporate Actions
J B Chemicals & Pharmaceuticals Ltd
₹9.3/Share
Announcement Date 29 May 2026
Record Date 29 May 2026
Div Yield 930%
J B Chemicals & Pharmaceuticals Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,789.45 | ₹4,29,349 |
| Divis Laboratories Ltd | ₹6,574.90 | ₹1,74,542.94 |
| Torrent Pharmaceuticals Ltd | ₹4,369.50 | ₹1,47,883.74 |
| Cipla Ltd | ₹1,375.05 | ₹1,11,076.61 |
| Zydus Lifesciences Ltd | ₹1,076.45 | ₹1,08,316.06 |
J B Chemicals & Pharmaceuticals Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Mirae Asset Healthcare Fund | 6.39% |
| AXIS Small Cap Fund | 2.23% |
| Franklin India Large Cap Fund | 2.20% |
| Canara Robeco Small Cap Fund | 2.08% |
| Kotak Midcap Fund | 1.55% |
J B Chemicals & Pharmaceuticals Ltd News
J B Chemicals & Pharmaceuticals AGM scheduled
On 17 June 2026
27 May 2026, 05:02 pm
J B Chemicals & Pharmaceuticals Ltd rises for third consecutive session
J B Chemicals & Pharmaceuticals Ltd is quoting at Rs 2243.5, up 2.32% on the day as on 12:49 IST on the NSE. The stock is up 31.82% in last one year as compared to a 4.24% spurt in NIFTY and a 14.46% spurt in the Nifty Pharma index.
25 May 2026, 01:05 pm
Board of J B Chemicals & Pharmaceuticals recommends final dividend
Of Rs 9.3 per share
12 May 2026, 09:44 am
J B Chemicals & Pharmaceuticals Ltd extends upmove
J B Chemicals & Pharmaceuticals Ltd is quoting at Rs 2144.9, up 0.08% on the day as on 12:44 IST on the NSE. The stock is up 40.69% in last one year as compared to a 0.65% jump in NIFTY and a 14.52% jump in the Nifty Pharma.
08 May 2026, 01:00 pm
J B Chemicals & Pharmaceuticals Ltd up for third straight session
J B Chemicals & Pharmaceuticals Ltd is quoting at Rs 2141, up 2.22% on the day as on 12:49 IST on the NSE. The stock is up 39.32% in last one year as compared to a 1.62% jump in NIFTY and a 12.19% jump in the Nifty Pharma index.
06 May 2026, 01:05 pm
J B Chemicals & Pharmaceuticals Ltd Stock Analysis
- Annual revenue for J B Chemicals & Pharmaceuticals Ltd increased by 4.99% to ₹3,945.17 crore in FY 2026 from ₹3,757.66 crore in FY 2025.
- Annual Net Profit for J B Chemicals & Pharmaceuticals Ltd increased by 3.30% to ₹674.10 crore in FY 2026 from ₹652.54 crore in FY 2025.
- Promoter Shareholding in J B Chemicals & Pharmaceuticals Ltd increased by 0.04% in the most recent quarter, from 48.78% in January 2026 to 48.80% in March 2026.
- J B Chemicals & Pharmaceuticals Ltd delivered a 1-year return of 26.50% compared to the Nifty 50, which provided a return of -4.63% as of the last trading session.
- J B Chemicals & Pharmaceuticals Ltd share price moved up by 0.15% from its previous close of INR ₹2,140. The latest J B Chemicals & Pharmaceuticals Ltd share price is INR ₹2,143.20.
- J B Chemicals & Pharmaceuticals Ltd share price today has been at a low of 2,121.70 and a high of 2,156.50. Over the past 52 weeks, the J B Chemicals & Pharmaceuticals Ltd share price has seen a low of 1,603.50 and a high of 2,285.30.
About J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) is a leading pharmaceutical company in India. It develops, manufactures, and markets pharmaceutical formulations, active pharmaceutical ingredients (APIs), and herbal remedies. The company operates in the Healthcare sector, specifically in the Pharmaceuticals sub-sector.
Established in 1976, JBCPL has many decades of experience in the pharmaceutical industry. The company's headquarters is located in Mumbai, Maharashtra, India. The company was founded by the Mody family, with J.B. Mody serving as the founding promoter. Currently, the company is majority-owned by KKR, a global investment firm that acquired a controlling stake in 2020.
JBCPL's main products include prescription pharmaceuticals, over-the-counter (OTC) products, and APIs. Some of their notable brands include Rantac (Ranitidine), Metrogyl (Metronidazole), and Cilacar (Cilnidipine). The company has a strong presence in the cardiovascular, gastrointestinal, and pain management segments.
JBCPL is not the top pharmaceutical company in India by overall market share or market capitalization. However, it has established leadership positions in specific therapeutic segments. For instance, Rantac has been among the leading brands in the antacid category in India.
The promoter shareholding stands at approximately 53.74%. This stake is entirely owned by TAU Investment Holdings Pte. Ltd. The current management team is led by CEO Nikhil Chopra. Also, the board of directors includes experienced professionals from the pharmaceutical industry. The managerial promoters of the company include:
Market Presence and Healthcare Access JBCPL has made significant contributions to healthcare accessibility through its diverse portfolio of affordable medications. The company's flagship products, particularly in the cardiovascular, gastrointestinal, and pain management segments, have helped millions of patients access quality healthcare at reasonable prices. Their brand, Rantac, for instance, has been instrumental in treating acid-related disorders. Also, the brand Cilacar has played a crucial role in hypertension management. The company's focus on producing quality generic medications has helped reduce the healthcare cost burden on patients and healthcare systems.
Manufacturing Excellence and Economic Impact The company's state-of-the-art manufacturing facilities in Gujarat. It has contributed significantly to local economic development through employment generation and skill development. These facilities, operating under strict quality control measures and international standards, have helped position India as a reliable pharmaceutical manufacturing hub. The company's export operations to over 50 countries. This has contributed to India's foreign exchange earnings. Also, this has strengthened its position in the global pharmaceutical supply chain.
Research and Innovation JBCPL's investment in research and development has fostered innovation in pharmaceutical formulations and manufacturing processes. Their R&D initiatives have not only led to the development of new drug delivery systems. However, it has contributed to the broader scientific knowledge base in the pharmaceutical sector. The company's focus on developing improved formulations has helped enhance treatment outcomes and patient compliance.
Employment and Skill Development As a major employer in the pharmaceutical sector, JBCPL has created numerous direct and indirect employment opportunities. The company's emphasis is on training and development. This has contributed to building a skilled workforce in the pharmaceutical industry. Their collaboration with educational institutions and training programs has helped bridge the skill gap in the pharmaceutical sector.
Corporate Social Responsibility The company's CSR initiatives have made meaningful contributions to community development, healthcare awareness, and environmental sustainability. Through various healthcare camps, educational programs, and community welfare projects, JBCPL has demonstrated its commitment to social responsibility and sustainable development.
Global Market Impact Post-KKR acquisition in 2020, JBCPL has strengthened its global presence and market reach. The company's international operations have helped establish Indian pharmaceutical capabilities in global markets, contributing to India's reputation as a 'pharmacy of the world.' Their compliance with international quality standards has set benchmarks for other pharmaceutical companies.
Environmental and Sustainability Initiatives JBCPL has implemented various environmental conservation measures in its manufacturing processes. This contributes to sustainable industrial development. They focus on reducing carbon footprint, waste management, and energy conservation. This has set examples for environmental responsibility in the pharmaceutical industry.
J.B. Chemicals & Pharmaceuticals Ltd's impact extends far beyond its business operations. The company has played a pivotal role in shaping India's pharmaceutical industry through its commitment to quality, innovation, and accessibility. It contributes to healthcare, economy, employment, and environmental sustainability. This demonstrates its position as a responsible corporate citizen. The company's journey serves as a testament to the potential of Indian pharmaceutical companies to create substantial value for all stakeholders while maintaining high standards of corporate responsibility and sustainable development.
Established in 1976, JBCPL has many decades of experience in the pharmaceutical industry. The company's headquarters is located in Mumbai, Maharashtra, India. The company was founded by the Mody family, with J.B. Mody serving as the founding promoter. Currently, the company is majority-owned by KKR, a global investment firm that acquired a controlling stake in 2020.
JBCPL's main products include prescription pharmaceuticals, over-the-counter (OTC) products, and APIs. Some of their notable brands include Rantac (Ranitidine), Metrogyl (Metronidazole), and Cilacar (Cilnidipine). The company has a strong presence in the cardiovascular, gastrointestinal, and pain management segments.
JBCPL is not the top pharmaceutical company in India by overall market share or market capitalization. However, it has established leadership positions in specific therapeutic segments. For instance, Rantac has been among the leading brands in the antacid category in India.
The promoter shareholding stands at approximately 53.74%. This stake is entirely owned by TAU Investment Holdings Pte. Ltd. The current management team is led by CEO Nikhil Chopra. Also, the board of directors includes experienced professionals from the pharmaceutical industry. The managerial promoters of the company include:
- Arun Duggal
- Prashant Kumar
- Gaurav Trehan
- Akshay Tanna
Impact of the Company
J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) has established itself as a significant player in the Indian pharmaceutical landscape since its inception in 1976. The company's journey from a modest beginning to becoming a prominent pharmaceutical manufacturer reflects its substantial impact on healthcare accessibility, economic growth, and industrial development in India and beyond.Market Presence and Healthcare Access JBCPL has made significant contributions to healthcare accessibility through its diverse portfolio of affordable medications. The company's flagship products, particularly in the cardiovascular, gastrointestinal, and pain management segments, have helped millions of patients access quality healthcare at reasonable prices. Their brand, Rantac, for instance, has been instrumental in treating acid-related disorders. Also, the brand Cilacar has played a crucial role in hypertension management. The company's focus on producing quality generic medications has helped reduce the healthcare cost burden on patients and healthcare systems.
Manufacturing Excellence and Economic Impact The company's state-of-the-art manufacturing facilities in Gujarat. It has contributed significantly to local economic development through employment generation and skill development. These facilities, operating under strict quality control measures and international standards, have helped position India as a reliable pharmaceutical manufacturing hub. The company's export operations to over 50 countries. This has contributed to India's foreign exchange earnings. Also, this has strengthened its position in the global pharmaceutical supply chain.
Research and Innovation JBCPL's investment in research and development has fostered innovation in pharmaceutical formulations and manufacturing processes. Their R&D initiatives have not only led to the development of new drug delivery systems. However, it has contributed to the broader scientific knowledge base in the pharmaceutical sector. The company's focus on developing improved formulations has helped enhance treatment outcomes and patient compliance.
Employment and Skill Development As a major employer in the pharmaceutical sector, JBCPL has created numerous direct and indirect employment opportunities. The company's emphasis is on training and development. This has contributed to building a skilled workforce in the pharmaceutical industry. Their collaboration with educational institutions and training programs has helped bridge the skill gap in the pharmaceutical sector.
Corporate Social Responsibility The company's CSR initiatives have made meaningful contributions to community development, healthcare awareness, and environmental sustainability. Through various healthcare camps, educational programs, and community welfare projects, JBCPL has demonstrated its commitment to social responsibility and sustainable development.
Global Market Impact Post-KKR acquisition in 2020, JBCPL has strengthened its global presence and market reach. The company's international operations have helped establish Indian pharmaceutical capabilities in global markets, contributing to India's reputation as a 'pharmacy of the world.' Their compliance with international quality standards has set benchmarks for other pharmaceutical companies.
Environmental and Sustainability Initiatives JBCPL has implemented various environmental conservation measures in its manufacturing processes. This contributes to sustainable industrial development. They focus on reducing carbon footprint, waste management, and energy conservation. This has set examples for environmental responsibility in the pharmaceutical industry.
J.B. Chemicals & Pharmaceuticals Ltd's impact extends far beyond its business operations. The company has played a pivotal role in shaping India's pharmaceutical industry through its commitment to quality, innovation, and accessibility. It contributes to healthcare, economy, employment, and environmental sustainability. This demonstrates its position as a responsible corporate citizen. The company's journey serves as a testament to the potential of Indian pharmaceutical companies to create substantial value for all stakeholders while maintaining high standards of corporate responsibility and sustainable development.
FAQ’s
What is the share price of J B Chemicals & Pharmaceuticals Ltd today?
J B Chemicals & Pharmaceuticals Ltd share price as on 4 Jun 2026 is ₹ 2143.2
What is the Market Cap of J B Chemicals & Pharmaceuticals Ltd?
The market cap of J B Chemicals & Pharmaceuticals Ltd stock is ₹34,359.56 Cr.
What is the PE Ratio of J B Chemicals & Pharmaceuticals Ltd?
The Price to Earnings (P/E) Ratio of J B Chemicals & Pharmaceuticals Ltd is 49.15
What is the PB Ratio of J B Chemicals & Pharmaceuticals Ltd?
The Price to Book (P/B) Ratio of J B Chemicals & Pharmaceuticals Ltd is 8.20
What is the 52 week high of J B Chemicals & Pharmaceuticals Ltd Share Price?
The 52 week high of J B Chemicals & Pharmaceuticals Ltd share price stands at ₹2,285.30
What is the 52 week low of J B Chemicals & Pharmaceuticals Ltd Share Price?
The 52 week low of J B Chemicals & Pharmaceuticals Ltd share price stands at ₹1,603.50
How can I buy shares of J B Chemicals & Pharmaceuticals Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of J B Chemicals & Pharmaceuticals Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
